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Abstract
Background
In some regions in Africa, elimination of onchocerciasis may be possible with mass drug
administration, although there is concern based on several factors that onchocerciasis can-
not be eliminated solely through this approach. A vaccine againstOnchocerca volvulus
would provide a critical tool for the ultimate elimination of this infection. Previous studies
have demonstrated that immunization of mice with Ov-103 andOv-RAL-2, when formulated
with alum, induced protective immunity. It was hypothesized that the levels of protective
immunity induced with the two recombinant antigens formulated with alum would be
improved by formulation with other adjuvants known to enhance different types of antigen-
specific immune responses.
Methodology/ Principal Findings
Immunizing mice withOv-103 andOv-RAL-2 in conjunction with alum, Advax 2 and MF59
induced significant levels of larval killing and host protection. The immune response was
biased towards Th2 with all three of the adjuvants, with IgG1 the dominant antibody.
Improved larval killing and host protection was observed in mice immunized with co-admin-
istered Ov-103 andOv-RAL-2 in conjunction with each of the three adjuvants as compared
to single immunizations. Antigen–specific antibody titers were significantly increased in
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mice immunized concurrently with the two antigens. Based on chemokine levels, it appears
that neutrophils and eosinophils participate in the protective immune response induced by
Ov-103, and macrophages and neutrophils participate in immunity induced byOv-RAL-2.
Conclusions/Significance
The mechanism of protective immunity induced byOv-103 andOv-RAL-2, with the adju-
vants alum, Advax 2 and MF59, appears to be multifactorial with roles for cytokines, chemo-
kines, antibody and specific effector cells. The vaccines developed in this study have the
potential of reducing the morbidity associated with onchocerciasis in humans.
Author Summary
In some regions in Africa, elimination of onchocerciasis may be possible with mass drug
administration, although there is concern based on several factors that onchocerciasis can-
not be eliminated solely through this approach. A vaccine against Onchocerca volvulus
would provide a critical tool for the ultimate elimination of this infection. Previous studies
have demonstrated that immunization of mice with two antigens induced protective
immunity and it was hypothesized in the present study that the levels of protective immu-
nity would be improved by formulation with other agents known to enhance immune
responses. Protective immunity was observed in mice immunized with the two antigens
using three different adjuvants. The vaccines developed in this study have the potential of
reducing the morbidity associated with onchocerciasis in humans.
Introduction
Onchocerciasis, caused by the filarial worm Onchocerca volvulus, is a neglected tropical disease
(NTD) endemic predominantly in Africa. The Global Burden of Disease Study 2013 estimate
indicates that 17 million people are currently infected with O. volvulus [1]. The disease, also
referred to as river blindness, is an important cause of blindness, skin disease and chronic dis-
ability. Moreover, in children from Uganda and South Sudan, there are links between O. volvu-
lus infection and a serious neurological disorder known as “nodding syndrome” [2, 3]. In some
endemic regions evidence suggests that elimination of onchocerciasis may be possible with
mass drug administration (MDA) of ivermectin [4]. Several significant obstacles must be over-
come before complete elimination in Africa can be achieved. First, it has been estimated that
elimination will require 14–35 years of continuous treatment [5, 6]. Furthermore, based on ani-
mal and human studies, susceptibility to reinfection increases after treatment [7–9]. In addi-
tion, there have been several reports which suggest that O. volvulus in some regions in Africa
may have developed resistance to ivermectin [10–18]. Finally, MDA of ivermectin is not possi-
ble in large areas of central Africa where loiasis is co-endemic, because of the risk of developing
severe adverse reactions to the treatment including encephalopathy in individuals with high
level of Loa loamicrofilaremia [19]. Therefore, there is a growing consensus supported by
mathematical modeling, that onchocerciasis in Africa will not be eliminated within the original
proposed timeframes using MDA alone. It has been estimated now that elimination would
require 1.15 billion treatments up until 2045, while other estimates suggest that onchocerciasis
cannot be eliminated solely through MDA with ivermectin [20, 21]. A vaccine against oncho-
cerciasis, to complement the present control measures, would therefore provide a critical tool
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for the ultimate elimination of this infection from humans [22, 23]. Mathematical modeling of
the impact of vaccination against O. volvulus suggests that a prophylactic vaccine would reduce
disease burden related to onchocerciasis in regions where ivermectin cannot be administered
safely and would decrease the chance of re-emergence of the parasite after mass drug adminis-
tration has been stopped [24].
A mouse model was developed for studying immunity to O. volvulus in which larvae are
implanted subcutaneously in mice within diffusion chambers [25]. Protective immunity was
demonstrated in this model following immunization of mice with irradiated third-stage infec-
tive larvae of O. volvulus [26–30]. The model was also used to identify recombinant antigens
that could be used in a vaccine against infection with larval O. volvulus [31, 32]. When some
of these recombinant antigens were produced under standardized conditions, two antigens
emerged as lead vaccine candidates, Ov-103 and Ov-RAL-2, based on their ability to induce
significant levels of protective immunity after immunization using alum as the adjuvant [33].
This observation was confirmed in gerbils immunized with the Brugia malayi proteins BM-
103 and Bm-RAL-2, which are orthologous to the O. volvulus proteins. Vaccination with BM-
103 and Bm-RAL-2, with alum as the adjuvant, induced protective immunity to infection with
B. malayi in gerbils [34]. Both proteins are highly conserved within nematodes and homologs
of these antigens have been shown to induce protective immunity to other nematodes [35–
41]. The functional properties of Ov-103 and Ov-RAL-2 are currently unknown, however,
both proteins are localized on the surface and glandular esophagus of third-stage larvae (L3)
as well as in the hypodermis and cuticle of adult worms and on the surface of microfilariae
[34, 42, 43].
The primary objective of the present study was to test the hypothesis that the levels of pro-
tective immunity induced with Ov-103 and Ov-RAL-2 formulated with alum could be
increased by formulating these antigens with immune enhancing adjuvants. Five adjuvants
(alum, Advax 1, Advax 2, CpG oligonucleotide (CpG), and MF59) were selected for compara-
tive analysis based on their ability to induce different types of immune responses. Alum, the
most commonly used adjuvant in human vaccines, elicits strong humoral immune responses,
which are mediated primarily by IgG1 [44, 45]. This adjuvant stimulates strong Th2 responses
but does not induce cell-mediated responses [46–50]. Injection of alum into mice increased the
expression of the neutrophil-specific chemokines CXCL1(KC) and CXCL2, the monocyte-spe-
cific chemokines CCL2 (MCP-1) and CCL4 (MIP-1β) and the eosinophil chemokines CCL11
(eotaxin-1) and CCL24 (eotaxin-2) [51, 52]. Alum appears to act mainly on macrophages and
monocytes to induce secretion of chemokines involved with cell recruitment from the blood
into peripheral tissues [53].
Advax 1 is a novel polysaccharide adjuvant derived from delta inulin [54] that is under
development for use in humans [55, 56]. It is successful at inducing a mixed Th1/Th2 associ-
ated IgG1 and IgG2a antibody response [57], as well as Th1, Th2 and Th17 cytokine responses
[58, 59]. Advax 2 is comprised of delta inulin formulated with a small amount of CpG, a TLR9
agonist which shifts some of the responses to Th1 while retaining the Th2 response. It also
potently induces CD8+ CTL and generally also gives the highest overall IgG response due to
induction of a broad combination of IgG1, IgG2 and IgG3 antibodies. CpG is a strongly Th-1
biased adjuvant that typically gives an IgG response comprised predominantly of IgG2 anti-
bodies [60, 61].
MF59, an oil-in-water emulsion adjuvant, has been established as safe and potent adjuvant
for use in human vaccines [62, 63]. This adjuvant induces a mixed Th1/Th2 response in
humans and animals [64, 65] with both antigen-specific IgG1 and IgG2a antibodies produced
[66], and has been shown to be more potent than alum for the induction of both antibody and
CD4+ responses [67, 68]. MF59 appears to act on macrophages, monocytes and granulocytes
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to induce secretion of MCP-1, CCL3 (MIP-1α), MIP-1β, all involved with cell recruitment
from blood into peripheral tissue [53].
Two criteria were used for measuring protective immunity in the present studies. The first
criterion was killing of parasites as represented by the comparison between the mean numbers
of larvae surviving in control vs. immunized mice. This metric assesses the ability of the
induced effector responses to kill worms and the capacity of all or part of the worm population
to evade the killing response. Parasite reduction is of particular importance in the case of
onchocerciasis since reducing worm burden would have a beneficial effect on health status,
without a requirement for achieving sterile immunity. The second measure was host protec-
tion, where the objective was to determine the number of immunized mice that had parasite
recovery below the 95% confidence interval seen in the control mice. This metric describes the
efficacy of the vaccine, by estimating what percent of vaccinees benefited from the prophylactic
vaccine. Reduced levels of infection within a population will likely enhance control of new
infections and thus disease within the endemic region.
A reductionist experimental approach was used in this study, with the initial screening of all
five adjuvants performed using Ov-103 as the antigen. Adjuvants that were successful at induc-
ing immunity with Ov-103 were then tested with Ov-RAL-2 and finally in a vaccine consisting
of co-administered Ov-103 and Ov-RAL-2. Analyses were performed to identify immune cor-
relates and potential mechanisms of protective immunity induced by the antigens, individually
or when co-administered, with the selected adjuvants. Once again, a reductionist experimental
approach was undertaken; all classes and sub-classes of antibody responses were initially tested
in mice immunized with Ov-103. Analyses of antibody response to Ov-RAL-2 and the Ov-103/
Ov-RAL-2 co-administered vaccine were then limited to the antibody subclasses that yielded
positive responses to Ov-103. Likewise, cytokine and chemokine responses were measured in
mice immunized with Ov-103 and the positive sub-sets measured in subsequent experiments.
Three adjuvants were identified that induced protective immunity with Ov-103 and Ov-RAL-2
and with the co-administered vaccine. Immunological correlates of protective immunity were
also observed based on unique antibody, cytokine and chemokine signatures.
Materials and Methods
Source of parasites and mice
O. volvulus L3 were collected from black flies (Simulium damnosum) that were fed on consent-
ing infected donors (Protocol 320 was approved by the New York Blood Center and the Medi-
cal Research Station, Kumba, Cameroon IRBs). After seven days the flies were dissected to
collect the developed L3, which were cleaned and cryopreserved as previously described [69].
Male BALB/cByJ mice, 6–8 weeks of age, were purchased from The Jackson Laboratory (Bar
Harbor Maine). All mice were housed in micro-isolator boxes in rooms that were pathogen
free and under temperature, humidity and light cycle controlled conditions in the Laboratory
Animal Sciences Facility at Thomas Jefferson University. Mice were fed autoclavable rodent
chow and given water ad libitum.
Animal ethics
All experimental procedures were performed in compliance with the ethical and regulatory
standards set by the NIH for animal experimentation. The animal use protocol (00136) was
approved by the Thomas Jefferson University Institutional Animal Care and Use Committee.
The animal care and use protocol adhered to the “Guide for the Care and Use of Laboratory
Animals” published by the National Research Council, USA.
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Production of antigens
Based on previous studies, Ov-103 was expressed in PichiaPink yeast and Ov-RAL-2 in Escheri-
chia coli. Antigens were prepared and analyzed as previously described [33]. In addition, Ov-
RAL-2 with His-tag at C-terminus was expressed in E. coli BL21, purified with nickel column
and endotoxin removed with a Q anion exchange column. The level of endotoxin in the final
products was less than 20EU/mg (13.2–19.3 EU/mg).
Immunization and challenge protocol
For experiments testing individual antigens, mice were immunized with 25 μg of the produced
vaccine antigen formulated with each of the five different adjuvants in a 100 μl total volume
preparation as per the manufacturer's directions. The alum immunization consisted of 50% v/v
of vaccine antigen in TBS and 1:5 Rehydragel LV (alum) in TBS (General Chemical, Parsip-
pany, NJ). Advax 1, Advax 2, and CpG (Vaxine Pty Ltd, Adelaide, South Australia) were used
at 1 mg of Advax 1 or Advax 2 or 10 μg of CpG mixed with vaccine antigen in TBS immediately
prior to injection. For vaccines formulated with MF59 (Novartis Vaccines, Cambridge, MA),
50 μl vaccine antigen in TBS was mixed 1:1 v/v with the adjuvant. Mice were immunized intra-
muscularly with 50 μl of the formulated vaccines in each caudal thigh. The Ov-103/Ov-RAL-2
co-administered vaccine consisted of 25 μg of each vaccine antigen, formulated with adjuvant
for a total of 50 μl; Ov-103 was injected in the left caudle muscle and Ov-RAL-2 in the right
caudal muscle. Immunization was followed by two booster injections 14 and 28 days later.
Cryopreserved L3 were defrosted in a two-step process, 15 minutes on dry ice followed
immediately by a 37° water bath. The thawed L3 were then washed 5 times in a 1:1 mixture of
NCTC-135 and Iscove's modified Dulbecco's medium supplemented with 100 U penicillin,
100 μg streptomycin, 100 μg gentamicin and 30 μg of chloramphenicol per ml. Diffusion cham-
bers were constructed from 14 mm Lucite rings covered with 5.0 μM pore-size Durapore mem-
branes (EMDMiIIipore, Billerca, CA) and fused together using an adhesive containing a 1:1
mixture of 1,2-dichloroethane (Fisher Scientific, Pittsburg, PA) and acryloid resin (Rohm and
Haas, Philadelphia, PA). The constructed diffusion chambers were then sterilized via 100% eth-
ylene oxide followed by 12 hr aeration.
Fourteen days after the final booster, mice were challenged using a diffusion chamber con-
taining 25 L3. The diffusion chambers were implanted in a subcutaneous pocket on the rear
flank of the mice. The diffusion chambers were recovered 21 days later and larval survival was
calculated based on the mobility and morphology of the remaining larvae. Protective immunity
was evaluated by two different methods: (1) Percent reduction of larvae, calculated by: ((Aver-
age worm survival in control mice—Average worm survival in immunized mice) Average
worm survival in control mice) x 100. (2) Host protection, calculated by: (Number of immu-
nized mice with parasite recovery levels below the 95 confidence interval of parasite recovery
in control mice total number of immunized mice) x 100. Cells within the diffusion chamber
were collected, placed onto slides by centrifugation using a Cytospin 3 (Shandon Inc, Pitts-
burgh, PA), and then stained and analyzed for differential cell counts using Hemastain 3
(Fisher Scientific).
ELISA
Serum for antigen-specific antibody analyses was collected when mice received challenge infec-
tions within diffusion chambers and at the conclusion of the experiment. lgG1, lgG2a, lgG2b,
lgG3, IgM and IgE were measured in mice immunized with Ov-103 with each of the five adju-
vants. Antigen-specific lgG1, lgG2a and lgG2b responses were measured in mice immunized
with Ov-RAL-2 and co-administered Ov-103/Ov-RAL-2 formulated alone or with either alum,
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Advax 2 or MF59. Maxisorp 96-well plates (Nunc Nalgene International, Rochester, NY) were
coated with 2 μg /ml of Ov-103 or Ov-RAL-2 in 50 mM Tris-CI coating buffer pH 8.8 overnight
4°C. Plates were washed with deionized water between each step. Borate buffer solution (BBS)
(0.17 M boric acid, 0.12 M NaCl, 0.5% Tween-20, 0.025% bovine serum albumin, I mM EDTA,
pH 8.2) was used to block the plates for 30 min at room temperature. Individual sera were
diluted to an appropriate starting concentration with BBS and serially diluted; plates were
sealed and incubated at 4°C overnight. Biotinylated anti-lgG1, -lgG2a, -IgG2b, -IgG3 and -IgE
(BD Biosciences, San Jose, CA) and -IgM (Vector Labs, Burlingame, CA) antibodies were
diluted 1:250 in BBS and incubated for 1 hr at room temperature. ExtrAvidin PX (Sigma,
St. Louis, MO) was diluted 1:1000 in BBS and added for 30 min at room temperature. After the
final wash, one component ABTS peroxidase substrate (KPL, Gaithersburg, MD) was added
and optical densities were read after 30 min at 405 nm in an iMark Microplate reader (Bio-
Rad, Hercules, CA). Endpoint titers were calculated as the lowest serum dilution from experi-
mental animals that had an optical density reading three times higher than the lowest optical
density recorded for control serum.
Spleen cell stimulation
One week after the diffusion chamber recovery, spleens from control and immunized mice
were aseptically removed and made into single cell suspensions. Cells were cultured in a
96-well plate at a concentration of 2x106/well. The cells were stimulated with either 10 μg of
Ov-103, Ov-RAL-2, media control or with anti-CD3 mAb (BD Biosciences) which was pre-
coated at 0.5 μg/ml for 2h at 37°C. Each well also received 0.5 μl of anti-IL-4r (BD Biosciences)
[70]. Cells were incubated at 37°C for 3 days, after which supernatants were collected and fro-
zen at -20°C.
Cytokine and chemokine measurements by Luminex. Supernatants from stimulated
spleen cell and the fluid from diffusion chambers recovered from mice immunized with Ov-
103 formulated with the five adjuvants were analyzed using Milliplex Map Kit magnetic bead
panels as per the manufacturer's protocol (EMDMiIIipore). Plates were analyzed on a MAG-
PIX Luminex machine (Austin, TX). All analyte concentrations were calculated using Milliplex
Analyst software (EMDMiIIipore). In the initial studies, 22 cytokines and 6 chemokines were
measured in both the supernatants from stimulated spleen cell and the fluid from diffusion
chambers. Elevated responses were recorded for 9 cytokines in the spleen cell supernatants and
5 chemokines in diffusion chamber fluid, as compared to controls. Analysis of cytokine and
chemokine levels in subsequent studies, with mice immunized with Ov-RAL-2 alone or in the
co-administered vaccine, were limited to the 9 cytokines in the spleen cell supernatants and 5
chemokines in diffusion chamber fluid (Table 1, S1 and S2 Tables).
Statistical analysis
All experiments consisted of 5–6 mice per group with the experiments performed at least twice
with consistent results between experiments. Data presented are cumulative from all experi-
ments. Data were analyzed for parasite killing by multifactorial analysis of variance ANOVA in
Systat v.ll (Systat Inc., Evanstown, IL). Probability values less than 0.05 were considered statisti-
cally significant. Bootstrap statistical analysis of host protection was performed using R pack-
age "boot". Bootstrap sample means were estimated from the control groups and the lower
bound of the 95% confidence interval reported. A kernel density estimate of the vaccine group
was calculated and the percentage below the bootstrap 95% confidence interval calculated.
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Results
Role of adjuvants in the induction of protective immunity
BALB/cByJ mice were immunized intramuscularly three times with Ov-103 or Ov-RAL-2 with-
out adjuvant. Control and immunized mice received challenge infections within diffusion
chambers, and there was no evidence of protective immunity in the immunized mice (Fig 1).
Cell migration into the diffusion chambers was equivalent between control and immunized
groups with 5 x 105 ± 8 x 105 cells found within the parasite microenvironment. The differen-
tial distribution of cells found within the diffusion chamber was neutrophils (48 ± 18%),
Table 1. Cytokines and chemokines measured by Luminex.
Cytokines Chemokines
Spleen Cells Diffusion Chamber
Elevated Equal Not Detected Elevated Not Detected
IFN-ƴ IL-1α IL-12p40 Eotaxin Rantes
IL-2 IL-3 IL-12p70 KC
IL-4 IL-22 IL-17/IL-25 MCP-1
IL-5 IL-28β IL-21 MIP-1α
IL-6 TNF-α IL-23 MIP-1β
IL-10 GM-CSF IL-33
IL-13 TNF-β
IL-17A
IL-17F
Cytokines and chemokines measured in spleen cell supernatants and diffusion chamber ﬂuid by Milliplex Map Kit magnetic bead panels on MAGPIX
Luminex. Results presented are for mice immunized with Ov-103, with cytokines only detected in the antigen-stimulated spleen cell supernatants and
chemokines only detected in the diffusion chamber ﬂuid. Elevated = increased levels in immunized mice as compared to controls. Equal = equal levels in
immunized and control mice. Not detected = levels not detected from control and immunized mice. Subsequent studies with Ov-RAL-2 were limited to
measurement of the 9 elevated cytokines from the spleen cell supernatants and 5 elevated chemokines from the diffusion chamber ﬂuid.
doi:10.1371/journal.pntd.0004797.t001
Fig 1. Survival ofOnchocerca volvulus in mice immunized withOv-103 orOv-RAL-2 without adjuvant.
Effect of immunization withOv-103 orOv-RAL-2 without adjuvant on the development of protective immunity
toOnchocerca volvulus larvae in mice. Each dot represents percent larval recovery from an individual animal.
Data presented are mean ± standard error.
doi:10.1371/journal.pntd.0004797.g001
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macrophages (48 ± 19%), lymphocytes (0 ± 0%) and eosinophils (5 ± 5%) in all groups of mice
regardless of treatment status.
Mice were immunized with Ov-103 formulated with one of the following five adjuvants:
alum, Advax 1, Advax 2, CpG or MF59. Immunization with Ov-103 in combination with alum,
Advax 2 and MF59 induced statistically significant reductions of larval survival (Fig 2). Mice
immunized with Ov-103 formulated with alum had reductions in mean larval survival of 30%
and host protection levels of 80%, with Advax 2 they had a 39% reduction in larval survival and
90% host protection and with MF59 they had a 32% reduction in larval survival and 75% host
protection. Vaccination of mice with Ov-103 formulated with Advax 1 or CpG as adjuvants did
not result in significant reductions in parasite survival yet they were associated with 35% and
68% host protection, respectively (Fig 2). Cell recruitment into diffusion chambers in control
and immunized mice were comparable between all adjuvants with 1.8 x 106 ± 1.6 x 106 total
cells and differential distribution of cells of neutrophils (56 ± 17%), macrophages (39 ± 16%),
lymphocytes (1 ± 1%) and eosinophils (4 ± 4%).
Ov-RAL-2 was tested as a vaccine in combination with the three adjuvants that induced pro-
tective immunity with Ov-103, specifically alum, Advax 2 and MF59. Immunization of mice
with Ov-RAL-2 formulated with each of these three adjuvants induced statistically significant
reductions in larval survival (Fig 3). Mice immunized with Ov-RAL-2 formulated with alum
had reductions in mean larval survival of 27% and 68% host protection, with Advax 2 mice had
a 35% reduction in larval survival and 85% host protection, and with MF59 mice had a 28%
reduction in larval survival and 87% host protection (Fig 3). Cell recruitment into the diffusion
chamber was comparable between all adjuvants with 1.4 x 106 ± 1.7 x 106 total cells and differ-
ential distribution of cells neutrophils (46 ± 17%), macrophages (49 ± 17%), lymphocytes
(0 ± 1%) and eosinophils (5 ± 4%).
Mice were immunized with co-administered Ov-103/Ov-RAL-2 formulated with alum,
Advax 2 andMF59. Immunization of mice with Ov-103 andOv-RAL-2 using all three adjuvants
Fig 2. Survival ofOnchocerca volvulus in mice immunized withOv-103 with five different adjuvants.
Effect of immunization withOv-103 formulated with the adjuvants alum, Advax 1, Advax 2, CpG or MF59 on
the development of protective immunity toOnchocerca volvulus larvae in mice. Each dot represents percent
larval recovery from an individual animal. Data lines presented are mean ± standard error. Asterisk
represents statistical difference in larval recoveries, p value 0.05. Dotted line is placed at the 95th
confidence interval for parasite recovery from control animals. % Reduction = percent reduction in parasite
survival in immunized mice as compared to controls. Host Protection = percentage of mice in the immunized
group with parasite recovery levels below the 95thconfidence interval for parasite recovery from control
animals.
doi:10.1371/journal.pntd.0004797.g002
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induced statistically significant reductions in larval survival (Fig 4). Mice immunized with the
two antigen co-administered vaccine formulated with alum, had reductions in mean larval sur-
vival of 38% and 100% host protection, with Advax 2 mice had a 47% reduction in larval sur-
vival and 80% host protection and with MF59 mice had a 29% reduction in larval survival and
Fig 3. Survival ofOnchocerca volvulus in mice immunized withOv-RAL-2 with three different
adjuvants. Effect of immunization withOv-RAL-2 formulated with the adjuvants alum, Advax 2 or MF59 on
the development of protective immunity toOnchocerca volvulus larvae in mice. Each dot represents percent
larval recovery from an individual animal. Data lines presented are mean ± standard error. Asterisk
represents statistical difference in larval recoveries, p value 0.05. Dotted line is placed at the 95th
confidence interval for parasite recovery from control animals. % Reduction = percent reduction in parasite
survival in immunized mice as compared to controls. Host Protection = percentage of mice in the immunized
group with parasite recovery levels below the 95thconfidence interval for parasite recovery from control
animals.
doi:10.1371/journal.pntd.0004797.g003
Fig 4. Survival ofOnchocerca volvulus in mice immunized withOv-103 andOv-RAL-2 co-
administered with three different adjuvants. Effect of immunization with theOv-103 andOv-RAL-2 co-
administered vaccines formulated with the adjuvants alum, Advax 2 or MF59 on the development of
protective immunity toOnchocerca volvulus larvae in mice. Each dot represents percent larval recovery from
an individual animal. Data lines presented are mean ± standard error. Asterisk represents statistical
difference in larval recoveries, p value 0.05. Dotted line is placed at the 95th confidence interval for parasite
recovery from control animals. % Reduction = percent reduction in parasite survival in immunized mice as
compared to controls. Host Protection = percentage of mice in the immunized group with parasite recovery
levels below the 95thconfidence interval for parasite recovery from control animals.
doi:10.1371/journal.pntd.0004797.g004
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67% host protection (Fig 4). Cell recruitment into the diffusion chamber was comparable
between all adjuvants with 1.0 x 106 ± 1.1 x 106 total cells and differential distribution of cells
neutrophils (40 ± 14%), macrophages (56 ± 15%), lymphocytes (0 ± 0%) and eosinophils
(4 ± 5%).
Antibody responses in mice immunized with Ov-103 or Ov-RAL-2
Immunization of mice with Ov-103 or Ov-RAL-2 without adjuvant did not induce a significant
IgG antibody response to either of the antigens. Antibody responses in mice immunized with
Ov-103 formulated with each of the five adjuvants, were measured in serum recovered from
mice at study termination. Mice immunized with Ov-103 formulated with each of the five adju-
vants had positive IgG1 responses, with CpG inducing the lowest endpoint titer. Ov-103-spe-
cific IgG2a responses were only discernible in mice immunized with Advax 2 as the adjuvant
(Table 2A). All immunized mice were negative for antigen-specific IgG2b, IgG3 and IgE. Con-
trol mice and mice immunized with Ov-103 formulated with any of the five adjuvants had
equivalent antigen-specific IgM responses. Analysis of serum, recovered at the same time
point, from mice immunized with Ov-RAL-2 was limited to IgG1, IgG2a and IgG2b. Mice
immunized with Ov-RAL-2 formulated with the adjuvants alum, Advax 2 or MF59 developed
positive IgG1, IgG2a and IgG2b antigen-specific responses. Enhanced IgG2a and IgG2b
responses were observed in mice immunized with Ov-RAL-2 formulated with Advax-2
(Table 2B). When antigen-specific antibody responses were measured in mice immunized with
the co-administered vaccines formulated with each of the three adjuvants, the Ov-103 and
Table 2. Antibody endpoint titers frommice immunized withOv-103,Ov-RAL-2, or co-administration ofOv-103 andOv-RAL-2 with adjuvant.
A. Ov-103
IgG1 IgG2a IgG2b
Alum 5,246 ± 4,538 ND ND
Advax 1 3,772 ± 2,602 ND ND
Advax 2 6,671 ± 3,893 773 ± 675 ND
Advax 3 285 ± 87 ND ND
MF59 7,254 ± 5,518 ND
B. Ov-RAL-2
IgG1 IgG2a IgG2b
Alum 33,250 ± 23,065 390 ± 504 88 ± 11
Advax 2 33,322 ± 44,332 11,599 ± 7,991 750 ± 519
MF59 6,635 ± 3,743 390 ± 504 88 ± 11
C. Ov-103
IgG1 IgG2a IgG2b
Alum 52,929 ± 49.748 ND ND
Advax 2 29,679 ± 29,034 7,986 ± 12,117 267 ± 289
MF59 32,042 ± 36,608 ND 260 ± 308
Ov-RAL-2
IgG1 IgG2a IgG2b
Alum 155,971 ± 82,299 354 ± 396 82 ± 92
Advax 2 84,890 ± 70,963 22,177 ± 25,587 4,289 ± 6,492
MF59 41,962 ± 27,352 180 ± 112 100 ± 63
IgG1, IgG2a and IgG2b antibody endpoint titers from mice immunized with Ov-103 (A), Ov-RAL-2 (B) or co-administration of Ov-103 andOv-RAL-2 (C) with
adjuvant. Serum samples were taken at the conclusion of the experiment. Values presented are mean ± standard deviation.
doi:10.1371/journal.pntd.0004797.t002
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Ov-RAL-2 antigen-specific IgG1 responses developed were significantly elevated as compared
to those seen in mice immunized with the corresponding single antigen vaccine. Antigen-spe-
cific IgG2a endpoint titers to Ov-103 and Ov-RAL-2 were only elevated in mice immunized
with Advax 2 as the adjuvant in the co-administered vaccines, as compared to mice immunized
with the single vaccines. Similarly, the IgG2b endpoint titers to Ov-RAL-2 were elevated in
mice immunized with the co-administered vaccines with Advax 2 as the adjuvant, as compared
to mice immunized with the Ov-RAL-2 formulated with Advax 2 (Table 2C).
Pre-challenge serum was collected from all mice and antibody class and sub-class responses
were measured. It was determined that the type and magnitude of the responses mirrored
those measured at study termination. Correlation analyses comparing parasite recovery num-
bers and antibody endpoint titers for both pre- and post-challenge serum did not reveal consis-
tent significant levels of statistical correlation.
Cytokine and chemokine responses in mice immunized with Ov-103 or
Ov-RAL-2
Twenty eight analytes were measured in both ex-vivo spleen cell stimulation supernatants and
fluid from diffusion chambers, collected at the time of parasite recovery, from mice immunized
with Ov-103 and formulated with each of the five adjuvants. Twenty-two cytokines were ana-
lyzed in the spleen cell supernatants and 9 were detected regardless of adjuvant used. All six of
the chemokines were negative in the spleen cell supernatants. The diffusion chamber fluids
were negative for all of the cytokines but had detectable levels of 5 chemokines (Table 1, S1A
and S2A Tables). Based on these observations, 9 cytokines were selected for further analysis in
the spleen cell supernatants and 5 chemokines were selected for analysis in the diffusion cham-
ber fluid collected from mice immunized with Ov-RAL-2 or the co-administered vaccines.
In the absence of adjuvant, immunization with either Ov-103 or Ov-RAL-2 induced elevated
antigen-stimulated IL-5 and IL-10 responses in the spleen cells (Table 3, S1B Table). All other
cytokines measured in the spleen cell supernatants, and chemokines measured in the diffusion
chamber fluid, were either not detected or responses were not different between control and
immunized mice. This observation suggests that both antigens predispose towards a Th2
Table 3. Fold differences in mean cytokine levels frommice immunized withOv-103,Ov-RAL-2, or co-administration ofOv-103 andOv-RAL-2 with
adjuvant.
No Adjuvant Ov103 OvRAL-2
Ov-103 Ov-RAL-2 Alum Advax 1 Advax 2 Advax 3 MF59 Alum Advax 2 MF59
Spleen Cell Stimulation
supernatant
IL-6 = = IL-6 3 3 = 3 2 IL-6 2 = 3
IL-2 = = IL-2 # # = = 6 IL-2 = = =
IFN-γ = = IFN-γ = = 1.6 # = IFN-γ = = =
IL-4 = = IL-4 3 = = = 3 IL-4 2 = 5
IL-5 4 3 IL-5 27 6 2 = 9 IL-5 2 3 18
IL-10 3 2 IL-10 6 4 4 3 8 IL-10 6 3 23
IL-13 ND ND IL-13 8 2.3 = = 3 IL-13 3 ND 8
IL-
17A
= = IL-
17A
2 = = ND 2 IL-
17A
= = 3
IL-17F = = IL-17F 2 = = = 2 IL-17F = = 2
Fold differences, as compared to values from controls, in mean cytokine levels from stimulated spleen cell cultures from mice immunized with Ov-103 and
Ov-RAL-2 with and without adjuvants, (=) same values in control and immunized mice; (#) decrease in mean cytokine levels in immunized mice as compared
to controls; (ND) not detected.
doi:10.1371/journal.pntd.0004797.t003
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immune response. This was confirmed when cytokines were measured in spleen cell superna-
tants from mice immunized with Ov-103 and Ov-RAL-2 formulated with each of the tested
adjuvants. A consistent observation was the increased production of IL-5 and IL-10, although
the levels varied based on vaccine antigen and adjuvant combination. Antigen-stimulated IL-4
and IL-13 levels were elevated in most of the groups, confirming the development of Th2
responses. In addition, there was an increase in IL-6 for both antigens when formulated with
all adjuvants except Advax 2. There was also an increase in IL-17A and IL-17F in mice immu-
nized with Ov-103 formulated with alum or MF59 and mice immunized with RAL-2 formu-
lated with MF59 (Table 3, S1A and S1C Table). Mice immunized with Ov-103/Ov-RAL-2 co-
administered vaccines formulated with each of the three adjuvants also preferentially induced
Th2 immune responses, based on the elevated levels of IL-5, IL-10 and IL-13 in the superna-
tants from ex vivo stimulated spleen cells (Table 4, S1D Table).
Mice immunized with Ov-103 or Ov-RAL-2 without adjuvants had equivalent but low levels
of the five measured chemokines in the diffusion chamber fluid, as compared to controls.
Interestingly, mice immunized with Ov-103 formulated with each of the three adjuvants that
induced protective immunity, shared the phenotype of having elevated KC and eotaxin in the
parasite microenvironment, in distinction to mice immunized with Ov-103 and Advax 1 or
CpG as adjuvants. Mice immunized with Ov-103 and MF59 as the adjuvant also had elevated
MCP-1, MIP1α and MIP1β (Table 5, S2B Table). In comparison, mice immunized with
Table 4. Fold differences in mean cytokine levels frommice immunized with co-administration ofOv-103 andOv-RAL-2 with adjuvant.
Alum Advax 2 MF59
Ov-103 Ov-RAL-2 Ov-103 Ov-RAL-2 Ov-103 Ov-RAL-2
Spleen Cell Stimulation supernatant IL-6 3 = 2 = 3 =
IL-2 2 = 2 2 = 2
IFN-γ 2 = 3 2 = =
IL-4 3 6 2 2 3 3
IL-5 10 15 11 = 10 9
IL-10 2 3 34 3 8 10
IL-13 10 5 14 ND 8 9
IL-17A = 3 3 = 3 6
IL-17F 4 3 = = 2 3
Fold differences, as compared to values from controls, in mean cytokine levels from stimulated spleen cell cultures from mice immunized with Ov-103 and
Ov-RAL-2 co-administered vaccines formulated with adjuvants. (=) same values in control and immunized mice; (#) decrease in mean cytokine levels in
immunized mice as compared to controls; (ND) not detected.
doi:10.1371/journal.pntd.0004797.t004
Table 5. Fold differences in mean chemokine levels frommice immunized withOv-103 orOv-RAL-2 with and without adjuvant.
No Adjuvant Ov103 OvRAL-2
Ov-103 Ov-RAL-2 Alum Advax 1 Advax 2 Advax 3 MF59 Alum Advax 2 MF59
Chamber Fluid KC = = KC 7 = 3 # 10 KC = = =
MCP-1 = = MCP-1 = = = # 9 MCP-1 3 2 =
MIP-1α = = MIP-1α = 2 = # 3 MIP-1α 3 2 =
MIP-1β = = MIP-1β = = = # 6 MIP-1β 6 = =
Eotaxin = = Eotaxin 5 = 2 2 2 Eotaxin = # =
Fold differences, as compared to values from controls, in mean chemokine levels from diffusion chamber ﬂuid from mice immunized with Ov-103 andOv-
RAL-2 with and without adjuvants. (=) same values in control and immunized mice; (#) decrease in mean cytokine levels in immunized mice as compared to
controls; (ND) not detected.
doi:10.1371/journal.pntd.0004797.t005
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Ov-RAL-2 with alum or Advax 2 as adjuvants had elevated MCP-1 and MIP1α, but did not
have increased KC or eotaxin (Table 5, S2C Table). Mice immunized with the co-administered
vaccine formulated with alum had elevated response to all five measured chemokines. Mice
immunized with the co-administered vaccine formulated with Advax 2 had elevated levels of
KC and mice immunized with MF59 as the adjuvant had elevated MCP-1 and MIP1β (Table 6,
S2D Table). Correlation analyses comparing mean-parasite-recovery numbers and cytokine or
chemokine levels did not reveal significant correlations.
Discussion
Mice immunized with Ov-103, Ov-RAL-2 or with co-administered Ov-103/Ov-RAL-2 formu-
lated with alum, Advax 2 or MF59 as the adjuvants consistently developed significant levels
of both larval killing and host protection. Immunization of mice with Ov-103 or Ov-RAL-2
without adjuvant did not induce protective immunity, although immunization with the anti-
gens stimulated recall IL-5 and IL-10 responses by spleen cells. The induction of a Th2
response by the antigens was anticipated, as evidence from both animal [27, 29] and human
studies [71, 72] demonstrate that O. volvulus infection typically induces Th2-type immunity.
Mice immunized with the two antigens without adjuvant did not develop antigen-specific
antibody responses and there was an absence of elevated host-chemokines within the parasite
microenvironment. In the absence of antibody and chemokine responses, the antigen-specific
Th2 cytokine response in the spleen was insufficient to induce protective immunity to the
infection.
Previous studies with Ov-103 and Ov-RAL-2 demonstrated that immunization with alum
as the adjuvant induced statistically significant levels of protective immunity [33]. The goal
of this study was to determine if altering the adjuvant could further enhance the induced pro-
tective immune response. Initial trials with Ov-103 compared five adjuvant formulations, of
which three, alum, Advax 2 and MF59, induced equivalent levels of larval killing and host
protection. Subsequent studies with Ov-RAL-2 confirmed that alum, Advax 2 and MF59
were effective adjuvants to induce equivalent levels of protective immunity. Co-administra-
tion of Ov-103 and Ov-RAL-2 with the three adjuvants induced significant larval killing and
host protection, in most cases equivalent to those seen in mice receiving single antigen immu-
nizations, as has been previously reported [31, 33]. However, in some instances there was a
trend to higher levels of protective immunity in mice receiving the co-administered vaccine.
The highest level of larval killing was 47% achieved in mice immunized with the two antigens
with Advax 2 as the adjuvant, with some individual animals in this group achieving levels of
larval killing of ~90%, which is higher than the maximal levels of larval killing achieved in
any of the other single or double antigen vaccine groups. The highest level of host protection
Table 6. Fold differences in mean chemokine levels frommice immunized with co-administration ofOv-103 andOv-RAL-2 with adjuvant.
Alum Advax 2 MF59
Chamber Fluid KC 2 2 =
MCP-1 2 = 2
MIP-1α 3 = =
MIP-1β 3 = 3
Eotaxin 2 = =
Fold differences, as compared to values from controls, in mean chemokine levels from diffusion chamber ﬂuid from mice immunized with Ov-103 andOv-
RAL-2 co-administered vaccines formulated with adjuvants. (=) same values in control and immunized mice; (#) decrease in mean cytokine levels in
immunized mice as compared to controls; (ND) not detected.
doi:10.1371/journal.pntd.0004797.t006
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of 100% was seen in mice immunized with co-administered vaccine plus alum. Similarly,
BM-103 and Bm-RAL-2, injected as a fusion protein or concurrently, induced more consis-
tent and enhanced levels of protective immunity in gerbils to B.malayi, as compared to levels
achieved with individual antigens [34]. Both of the metrics used in this study, larval killing
and host protection, are integral in the evaluation of a vaccine. A reduction in worm burden
of approximately 50% would translate into a significant decrease in disease in the vaccinated
individual and a reduction in potential transmission of infection. Host protection of 100%
indicates that all vaccinated individuals responded in an efficacious manner to the vaccine
and reduced infection burden, which is an important indicator of the robustness of the
vaccine.
The dominant antibody isotype that was produced after immunization with Ov-103 and the
five adjuvants and Ov-RAL-2 with the three adjuvants was IgG1. Only vaccines with Advax-2
induced significant IgG2a/b responses, consistent with the mixed Th1/Th2 response previously
reported for this adjuvant [57–59]. The IgG1-dominated response could be predicted based on
the Th2 nature of the response induced by Ov-103 and Ov-RAL-2 antigens [73]. Antigen-spe-
cific IgE was not measureable in any of the immunized mice in this study. However, IgE was
shown to be a component of the protective immune response to O. volvulus induced by irradi-
ated larvae [26]. The protective immune response induced with the recombinant antigens
therefore differs from the mechanism induced by irradiated larvae. The absence of an IgE
response induced by Ov-103 and Ov-RAL-2 is a significant benefit, as it reduces the possibility
of adverse allergic responses when the vaccine is used clinically [74]. Finally, antigen-specific
IgM levels at the terminal bleed were equivalent in control and immunized mice. This suggests
that parasites within the diffusion chambers implanted in control mice released the antigens
that induced an IgM response rather than this reflecting a response primed by the vaccine.
Immunization with Ov-RAL-2 stimulated much higher antibody endpoint titers than Ov-
103, but this did not translate to higher levels of protective immunity. Likewise, immunization
with co-administered Ov-103/Ov-RAL-2 vaccines further increased the antibody endpoint
titers but with inconsistent increases in protective immunity. Correlation analysis using both
pre-challenge and study termination sera was performed in an attempt to identify potential
components of the killing mechanism. A clear relationship between antibody titer and protec-
tive immunity was not observed. Antibody is required for killing larval O. volvulus after immu-
nization with irradiated larvae [26]. The quantity of antibody may not be a limiting factor to
kill the larvae, with only a low titer of antibody required to effect larvae killing and hence any
potential correlations were possibly obscured in the present study.
In previous studies mice were immunized with Ov-103 and Ov-RAL-2 as fusion proteins
with alum as the adjuvant. The levels of larval killing (11–21%) and host protection (45–58%)
[33] were significantly less than observed in the present study, where the two antigens were co-
administered in separate sites. Immunization of mice with both antigens, either as a fusion pro-
tein [33] or as co-administration, resulted in significantly higher antibody endpoint titers as
compared to mice immunized with the antigens individually. Apparently, the two antigens act
synergistically to boost the antibody response to the reciprocal antigen. This is in distinction to
other O. volvulus antigens that were found to compete with each other in vaccines resulting in
reduced antibody titers [31]. Changing the route of immunization from subcutaneous, used in
the previous studies [31, 33], to intramuscular, used in the present study, may have enhanced
the protective immune response.
Immunization of mice with the Ov-103 or Ov-RAL-2 without adjuvant induced spleen cells
to produce Th2 cytokines. A consistent observation regarding Ov-103 and/or Ov-RAL-2 in
combination with the different adjuvants, was the development of Th2 immune responses
based on the presence of the cytokines IL-4, IL-5, IL-10 and IL-13 in supernatants from re-
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stimulated spleen cells. It was predicted that the adjuvants would govern the immune response
with alum stimulating a restricted Th2 response [46–50], Advax 1 stimulating mixed Th1 and
Th2 responses [58, 59], Advax 2 stimulating an increased Th1 response while retaining the
Th2 response, CpG stimulating a Th1 response [60, 61], and MF59 stimulating a mixed Th1/
Th2 response. Apparently, the Th2 nature of the antigens and the larval challenge was suffi-
cient to dominate the immune response even under the pressure produced by the more Th1
biased adjuvants. The cytokine recall response in mice was limited to Th2 cytokines, with the
exception of mice immunized with Advax 2. Two to three fold increases in the IFNγ recall
responses were seen in mice immunized with Advax 2 plus either Ov-103 or the co-adminis-
tered vaccine. Antibody responses in mice immunized with Ov-103, Ov-RAL-2 or the co-
administration with Advax 2 resulted in a combined IgG1 and IgG2a/b response, consistent
with a mixed Th1/Th2 response. Immunizing mice with inulin as the adjuvant with other filar-
ial antigens derived from B.malayi, demonstrated that the adjuvant induced a balanced Th1/
Th2 response [75]. In the present study, a limited Th2 cytokine response and positive IgG1
titers was seen in mice immunized with Ov-103 and Advax 1 or CpG, yet parasite killing was
absent. Surprisingly, the CpG adjuvant was unable, despite its normal Th1 bias, to induce an
IFNγ response to Ov-103 or IgG2 isotype switching, consistent with Ov-103 antigen imparting
an overwhelming Th2 bias to the adaptive immune response.
Examination of the diffusion chamber contents allowed analysis of the immune response in
the parasite microenvironment. Differential cell analyses were performed and relationships
were not seen between specific cell types and the presence of protective immunity in mice. In
addition, differences were not seen between the numbers of cells that migrated into the diffu-
sion chambers implanted in control and immunized mice. As an alternative approach to deter-
mine the effector cells involved with parasite killing, chemokine levels were measured in the
fluid found in the diffusion chambers in which the parasites were implanted. A similar
approach has been utilized in studying serum from patients with occult infections with O. vol-
vulus. With expiring microfilariae infections, MIP-1 α and MIP-1β levels increased while after
treatment with ivermectin, eotaxin and MCP-1 increased, which may have attracted effector
monocytes and eosinophils to clear the microfilariae from the skin of the patients [76]. Mice
immunized with Ov-103 formulated with alum, Advax 2 or MF59, in which there was protec-
tive immunity, had increased levels of the chemokines KC and eotaxin as compared to controls.
These increases were not seen in mice immunized with Ov-103 alone or when formulated with
Advax 1 and CpG, which suggests that either these chemokines were critical for the killing
response induced by Ov-103 or were produced as a secondary response to larval killing. KC is
involved in the activation and chemotaxis of neutrophils [77, 78]. Eotaxin is a potent chemoat-
tractant of eosinophils and basophils by binding CCR3 [79, 80]. Based on the chemokine obser-
vations, we hypothesize that protective immunity induced by Ov-103 formulated with alum,
Advax 2 or MF59 requires neutrophils and/or eosinophils as effector cells that collaborate with
antibody. Neutrophils with antibody have been shown to be effective at killing larval O. volvu-
lus in vitro [81] and in vivo studies have shown that eosinophils with antibody are capable of
killing O. volvulus larvae [26].
Elevated levels of the chemokines MIP-1α and MCP-1 were found in diffusion chambers
recovered from mice with protective immunity induced by Ov-RAL-2, but not Ov-103, when
formulated with alum or Advax 2. This observation suggests that the mechanism of protective
immunity induced by Ov-RAL-2 differs from the mechanism induced by Ov-103. MIP-1α is
involved in the recruitment and activation of granulocytes including neutrophils during the
acute inflammatory response [82–84]. MCP-1 exhibits a chemotactic activity for monocytes
and basophils but not for neutrophils or eosinophils [80, 85, 86]. Chemokine results from pro-
tected mice vaccinated with Ov-RAL-2 formulated with alum or Advax 2 suggest that the
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effector cells required for protective immunity induced by Ov-RAL-2 might be macrophages
and/or neutrophils. Macrophages from mice and humans have been shown to kill nematode
larvae in both the innate and adaptive immune response. Furthermore, optimal killing required
both neutrophils and macrophages to be active [87].
Chemokine levels in diffusion chambers from mice immunized with the co-administered
vaccine displayed disparate responses. In mice immunized with the co-administered vaccine
formulated with Advax 2 and MF59, chemokine levels were similar to those seen in mice
immunized with Ov-103 but different from that seen in mice immunized with Ov-RAL-2, sug-
gesting that with these adjuvants Ov-103 is the dominant antigen. Chemokines in mice immu-
nized with the co-administered vaccine formulated with alum, had chemokines found to be
associated with both of the individual antigen vaccines. The combined chemokine response
might explain the development of 100% host protection in mice immunized with Ov-103 and
Ov-RAL-2 co-administered vaccines formulated with alum.
Cytokines found in the spleen-cell supernatants also support a role for eosinophils, neutro-
phils and macrophages in the protective immune responses. All of the immunized mice had
elevated levels of IL-5, which has been shown to be required for eosinophil differentiation, mat-
uration and survival [88]. Mice immunized with Ov-103 formulated with alum or MF59 and
mice immunized with Ov-RAL-2 formulated with MF59 also had increases in IL17A/F, consis-
tent with a Th17 response. IL-17 has been shown to promote the production of IL-6, IL-8,
G-CSF, and GM-CSF [89–91], and was demonstrated to induce numerous proinflammatory
chemokines including MCP-1 and GRO-α that lead to monocyte and neutrophil recruitment
[92–94]. However, the fact that mice immunized with vaccines formulated with Advax 2
induced robust larval killing despite not inducing IL17 suggests IL17 is not critical for vaccine
protection. Immunization of mice with Ov-103 or Ov-RAL-2 formulated with alum or MF59
also resulted in production of IL-6 from stimulated spleen cells. IL-6 has been shown to play a
crucial role in both innate and adaptive immune response, and along with IL-1β and TNFα
attracts neutrophils during the initial phase of the immune response. Following the initial
response, IL-6 trans-signaling leads to a switch from neutrophil recruitment to monocyte
recruitment by suppressing many cytokines involved in the recruitment of neutrophils. Fur-
ther, it upregulates a number of monocyte-attracting chemokines such as MCP-1 [95–98].
However, the protection in the Advax 2 group in the absence of a significant IL-6 response
again argues against a key role of IL-6 in larval killing.
In conclusion, immunizing mice with the recombinant antigens Ov-103 and Ov-RAL-2 for-
mulated with alum, Advax 2 or MF59 induced significant levels of larval killing and host pro-
tection. The immune response was biased towards Th2 with all three adjuvants, with IgG1 the
dominant antibody induced in response to both antigens. Only Advax 2 induced high levels of
IgG1 and IgG2a/b antibodies to both antigens. Co-administration of Ov-103/Ov-RAL-2 formu-
lated with each of the three adjuvants induced larval killing, improved host protection and sig-
nificantly increased antibody titers. Based on chemokine results, it appears that neutrophils
and eosinophils may play a role in protective immunity induced by Ov-103 and macrophages
and neutrophils in protective immunity induced by Ov-RAL-2. The co-administered vaccines,
comprised of immunizations with both Ov-103 and Ov-RAL-2 antigens, had enhanced efficacy
in controlling infections with O. volvulus, potentially based on the collaboration of two unique
but synergistic killing mechanisms. Therefore, the mechanism of protective immunity induced
by Ov-103 and Ov-RAL-2 formulated with alum, Advax 2 or MF59 appears to be multifactorial,
with roles for antibody, cytokines, chemokines and specific effector cells. Further improving
these vaccines will require strategies to optimize levels of all these protective mechanisms that
contribute to larval killing.
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